Asuragen Signs Deal with Novartis to Develop Standardization Tools for BCR-ABL Monitoring

Asuragen is developing BCR-ABL calibrators that "are intended to be compatible with several widely used assays," as well as a software reporting tool that is "expected to help standardize how BCR-ABL1 RT-qPCR results are reported according to the International Scale."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.